Clinical Trial Detail

NCT ID NCT03835533
Title Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Parker Institute for Cancer Immunotherapy
Indications

prostate cancer

Therapies

CDX-301 + INO-5151 + Nivolumab

CDX-301 + Nivolumab + Poly ICLC

Nivolumab + NKTR-214

Age Groups: adult senior

No variant requirements are available.